الفهرس 
PreeclampsiaOnly 14 pages are availabe for public view
 |  | from | 249 |  |  |
| | | from | 249 | | |
Abstract
Preeclampsia is a pregnancy-specific disease, which affects
approximately 5% of all pregnancies and characterized by
hypertension (blood pressure ≥140/90mmHg), as well as a
systemic disease, which is commonly accompanied by
proteinuria (≥300 mg/24-h urine collection). It occurs after 20
weeks of gestation, is a leading cause of fetal and maternal
morbidity and mortality and may be characterized by abnormal
placental vessel formation (placental preeclampsia), or by
endothelial dysfunction that predates pregnancy in women with
preexisting hypertension, diabetes, or obesity (maternal
preeclampsia). The etiologic factors causing this disease are still not
completely clear, although evidence support involvement of genetic,
immune, angiogenic, and other mechanisms.
Pentraxin (PTX3) is a recently described inflammatory
molecule that belongs to the same family of the well-known
C-reactive protein(CRP). PTX3 differs from CRP in terms of
cellular origin, molecular inducers, and kinetic of
production. It is expressed by different cells like endothelial
cells, monocytes, macrophages, and fibroblasts exposed to
inflammatory stimuli. Placental protein 13 (PP13) is a member
of the galectin family of sugar-binding proteins and is also called
galectin 13 (GAL-13). This protein is expressed by the placenta
from the time of trophoblast fusion to form the
syncytiotrophoblast layer. Galectin-14 (Gal-14) is a recently
discovered member of the galectin family specifically expressed
by ovine eosinophils. SheepLOC443162 encodes ‘galectin-14’, a
protein that is more closely related to galectin-9 rather than to
eosinophils where it plays a role in allergic inflammation.The aim of this study was to evaluate the potential role of serum
galectin-13 and galectin-14 in comparison to Pentraxin 3 in
Egyptian patients and that potentially may be used to predict the
onset or monitor the progression of preeclampsia. We also
compared and correlate these markers with the routine diagnostic
markers
Ninety Egyptian subjects, including patients with
preeclampsia, and healthy controls of similar age and gender
(control group), were enrolled in this study. Serum levels of
galectin-13, galectin-14 and Pentraxin 3 were measured using
ELISA technique. The levels of Lipid profile including (TC,
TAG, LDL-c & HDL-c), liver function tests including (ALT,
AST, ALP, GGT, Bilirubin & total protein), kidney function tests
including (Creatinine, uric acid& microalbumin), ESR, CRP,
CBC, glucose and HbA1c were also analyzed.
The results of the present study were clearly indicated that:
Levels of PTX-3, GAL-13 and GAL-14 to be higher in the PE
group than in the control group.
In the meantime, results of lipid profile (except HDLc) were
significantly higher in the PE group than in the control group.
A highly significant negative correlation was shown between
GAL-13 and TAG and a significant negative correlation was
shown between GAL-13 and GGT also between PTX-3 and
Bilirubin. In the meantime, A significant positive correlation
was shown between GAL-14 and PTX-3 also between GAL-
14 and ALP in 1st trimester group of PE patients.
A highly significant positive correlation was observed between
GAL-14 and PTX-3 also, a significant positive correlation was
shown between GAL-14 & AST. In the meantime, a significant negative correlation was observed between GAL-
13 and PTX3 in 2nd trimester group of PE patients.
A significant positive correlation was shown between GAL-14
and Bilirubin also between PTX-3 and Glucose in 3rd trimester
group of PE patients.
PTX-3, GAL-13 and GAL-14 showed high accuracy in the
preeclampsia group. While, CRP yielded a worse accuracy for
diagnosing of preeclampsia.
In conclusion, PTX-3, GAL-13 and 14 may be early, highly
sensitive and specific markers and they could be used as a useful
promising biomarker for early detection of preeclampsia.
Targeting on reducing their levels may be specific therapeutic
interventions to prevent preeclampsia progression. While CRP
couldn’t be used as a reliable diagnostic biomarker for this
disease. Future studies should focus on social and genetic
determinants of inflammation and their association with PE in
Egyptian preeclampsia patients.